NY-MORROW-SODALI
Morrow Sodali announced today that Debt Capital Markets industry experts Damian Watkin, Damir Hadžiosmanović, Ken Abela and Tina Siu, have joined the firm as part of a global strategy to strengthen its bonds-related services offering.
The team, which provides 50+ years of combined experience working on over 800 debt-related deals, joins Morrow Sodali from D.F. King and will be based in London and Hong Kong, bolstering the firm’s global presence in Debt Services. They will work alongside leading in-house expert Pia Gowland who from now on will oversee Morrow Sodali’s Debt Services activities in the Americas.
Damian Watkin, who joins Morrow Sodali as a Senior Director in the firm’s London office, brings 20 years’ experience in the capital markets industry working with global financial institutions, corporate and sovereign issuers, with extensive expertise in executing liability management and debt restructuring transactions and researching ownership in capital structures. In his previous role at D.F. King, Mr. Watkin built and led the firm’s bonds business outside of the US market, working with a broad range of debt issuers, and their advisors, in some of the largest or highest profile transactions of recent years.
“We are very excited to join the entrepreneurial and client-focused team at Morrow Sodali and be able to offer a seamless service from a truly global and technology-led execution platform to bond issuers and their advisers,” said Mr. Watkin. “Morrow Sodali now has a global footprint, with experienced execution professionals based in Asia, Europe and the Americas.”
Joining Mr. Watkin in London as a Director, Damir Hadžiosmanović has nearly 20 years’ experience in working with corporate and sovereign issuers, assisting them in executing various liability management transactions and bondholder identifications, as well as debt restructurings and schemes of arrangement.
Ken Abela, who joins Morrow Sodali as a Director, brings nearly 20 years’ experience, of which 17 years in Asia, in assisting corporate and sovereign issuers in executing liability management and debt restructuring transactions. Mr. Abela will be based in Hong Kong and will be responsible for strengthening the firm’s Debt Services offering across Asia Pacific markets.
“We are looking forward to expanding Morrow Sodali’s debt-related services in Asia, providing bond issuers and their advisors in the region with an experienced local point of contact, with the ability to assist with transactions and provide advice to practitioners in their own time zone,” said Mr. Abela.
Joining Mr. Abela in Hong Kong, Tina Siu has assisted in providing D.F. King’s debt-related activities led by Mr. Abela, with a strong track record of supporting bond issuers in executing liability management transactions across Asian markets. Prior to D.F. King, Ms. Siu worked with financial institutions focusing on debt market research as well as conducting financial analysis for corporate clients.
Morrow Sodali Global Corporate Director Giulio Pediconi commented: “We are delighted to welcome such an experienced team within the Morrow Sodali family. With the global expansion of corporate debt markets, our combined expertise across our dedicated hubs in New York, London and Hong Kong will enable us to expand our services and offer our clients a truly global coverage in this key market.”
About Morrow Sodali
Morrow Sodali is a leading provider of strategic advice and shareholder and bondholder services to corporate and sovereign clients around the world. The firm provides corporate boards and executives with strategic advice and services relating to corporate governance, shareholder and bondholder communication and engagement, capital markets intelligence, proxy solicitation, shareholder activism, mergers and acquisitions and debt-related transactions.
From headquarters in New York and London, and offices and partners in major capital markets, Morrow Sodali serves more than 700 corporate clients in 40 countries, including many of the world’s largest multinational corporations. In addition to listed and private companies, its clients include mutual funds, ETFs, stock exchanges and membership associations.
For further information about Morrow Sodali, please visit www.morrowsodali.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom